Company Profile
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (87.8%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (19.9%);
- sale of animal health products (11.4%);
- other (0.8%).
Net sales are distributed geographically as follows: the United States (46%), Europe/Middle East/Africa (27.4%), China (9%), Japan (5.6%), Asia/Pacific (4.9%), Latin America (4.5%) and other (2.6%).
- sale of pharmaceutical products (87.8%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (19.9%);
- sale of animal health products (11.4%);
- other (0.8%).
Net sales are distributed geographically as follows: the United States (46%), Europe/Middle East/Africa (27.4%), China (9%), Japan (5.6%), Asia/Pacific (4.9%), Latin America (4.5%) and other (2.6%).
Source: Cofisem - Last Update: 2023-05-24
Key Executives
| Chairman and Chief Executive Officer | |
| Chief Financial Officer | |
| Company Secretary | |
| Chief Strategy Officer | |
| Human Resources Director | |
| Director of Information Systems | |
| Chief Communication Officer |
Source: Cofisem - Last Update: 2023-01-03
Key Figures
| Millenium | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Net sales | 55,534,946 | 43,009,537 | 33,809,446 | 41,826,657 | 36,977,067 |
| Cost of sales | 16,310,223 | 12,032,851 | 11,089,577 | 12,601,575 | 11,810,734 |
| Personnal costs | 0 | 0 | 0 | ||
| Operating income | 16,810,462 | 11,072,059 | 4,049,674 | 10,236,994 | 7,607,166 |
| Income tax | 1,796,738 | 1,343,165 | 1,391,694 | 1,506,438 | 2,192,710 |
| Net income | 13,607,622 | 11,534,793 | 5,758,143 | 8,730,556 | 5,414,455 |
| Net consolidated income (Group share) | 13,601,064 | 11,523,313 | 5,754,886 | 8,789,492 | 5,438,061 |
| Fiscal year end | 12.22 | 12.21 | 12.2 | 12.19 | 12.18 |
| Length of fiscal year (month) | 12 | 12 | 12 | 12 | 12 |
| Currency & Unit | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands |
| Account Standards |
Source: Cofisem - Last Update: 2023-05-24
Shareholder information
| The Vanguard Group, Inc. | |
| BlackRock, Inc. |
Source: Cofisem - Last Update: 2023-05-24
Address
Merck & Co., Inc.
2000 Road Galloping Hill
PO Box 100
NJ 07033 Kenilworth, New Jersey
United States
Phone number: +1 (908) 740-4000
https://www.merck.com/investor-relations/
Source: Cofisem - Last Update: 2023-05-24
Please contact MyQuestion.Italy@euronext.com for Company Profile support.